APYX
Apyx Medical·NASDAQ
--
--(--)
--
--(--)
APYX fundamentals
Apyx Medical (APYX) released its earnings on Mar 10, 2026: revenue was 19.16M (YoY +34.75%), beat estimates; EPS was -0.03 (YoY +75.00%), beat estimates.
Revenue / YoY
19.16M
+34.75%
EPS / YoY
-0.03
+75.00%
Report date
Mar 10, 2026
APYX Earnings Call Summary for Q4,2025
- Revenue Surge: Q4 2025 revenue up 35% to $19.2 million, driven by AYON's 38% Surgical Aesthetics growth. AYON captured 38% of sales from new customers, with 80% upgrades from existing Renuvion users.
- Market Leadership: AYON, the first fully integrated body contouring system, is FDA-cleared and awaits power-assisted liposuction approval in mid-2026. International expansion targets Europe, Brazil, and Colombia.
- Financial Resilience: $31.7 million cash reserves; 2026 guidance of $57.5-58.5 million revenue with 61-62% gross margins. Cash flow positive by Q4 2026.
- Strategic Growth: Hiring top-tier sales talent to leverage GLP-1 drug-driven demand. Renuvion remains key for standalone sales outside the U.S.
EPS
Actual | -0.06 | -0.14 | -0.11 | -0.04 | -0.14 | -0.12 | -0.12 | -0.06 | -0.17 | -0.16 | -0.17 | -0.17 | -0.1 | -0.03 | -0.13 | -0.28 | -0.22 | -0.19 | -0.14 | -0.12 | -0.1 | -0.09 | -0.05 | -0.03 | ||||||||||
Forecast | -0.25 | -0.2125 | -0.165 | -0.1075 | -0.145 | -0.1475 | -0.15 | -0.11 | -0.1467 | -0.1875 | -0.145 | -0.1425 | -0.135 | -0.07 | -0.114 | -0.178 | -0.216 | -0.198 | -0.184 | -0.1596 | -0.12 | -0.0933 | -0.1024 | -0.055 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | +76.00% | +34.12% | +33.33% | +62.79% | +3.45% | +18.64% | +20.00% | +45.45% | -15.88% | +14.67% | -17.24% | -19.30% | +25.93% | +57.14% | -14.04% | -57.30% | -1.85% | +4.04% | +23.91% | +24.81% | +16.67% | +3.54% | +51.17% | +45.45% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.00M | 4.30M | 6.95M | 11.46M | 8.64M | 11.22M | 11.80M | 16.82M | 12.49M | 10.29M | 9.11M | 12.61M | 12.14M | 13.57M | 11.98M | 14.66M | 10.24M | 12.15M | 11.49M | 14.22M | 9.43M | 11.37M | 12.88M | 19.16M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.20M | 1.97M | 5.69M | 10.27M | 7.84M | 8.86M | 10.20M | 14.63M | 11.12M | 10.56M | 12.01M | 12.94M | 10.84M | 14.33M | 15.37M | 14.85M | 9.53M | 11.75M | 11.38M | 13.39M | 9.39M | 11.70M | 12.00M | 18.54M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -3.93% | +118.63% | +22.14% | +11.67% | +10.18% | +26.66% | +15.73% | +15.02% | +12.33% | -2.51% | -24.11% | -2.51% | +12.06% | -5.28% | -22.08% | -1.29% | +7.53% | +3.36% | +0.96% | +6.18% | +0.44% | -2.79% | +7.30% | +3.37% |
Earnings Call
You can ask Aime
What guidance did Apyx Medical's management provide for the next earnings period?What were the key takeaways from Apyx Medical's earnings call?What is Apyx Medical's gross profit margin?What were the key takeaways from Apyx Medical’s earnings call?What is the market's earnings forecast for Apyx Medical next quarter?What is Apyx Medical's latest dividend and current dividend yield?Did Apyx Medical beat or miss consensus estimates last quarter?What factors drove the changes in Apyx Medical's revenue and profit?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
